

Board Changes

TALi Digital Ltd (ASX: TD1, "TALi" or "the Company") is pleased to announce the following Board changes.

As of 6th October 2022, Sue MacLeman will step down as Chair and Non Executive Director at TALi in order to dedicate more time to her other roles. Sue joined the TALi Board as Chair in September 2018 and led the Board during significant transitions, including the change from Novita Healthcare to TALi Digital. Sue feels that with the changes at the Executive level and the new company business direction and strategies, now is a proper time for renewal at the Board level. We thank her sincerely for her guidance and diligence over the last four years and especially in her knowledge in medical device commercialisation.

Also, Jefferson Harcourt has decided to resign from the TALi Board of Directors to pursue his interests in his other businesses. Jefferson has been with TALi since its inception in 2016. We will miss his deep passion for the TALi products and thank him for his input over the last 5 years. This change is also with effective 6th October 2022.

Coming back to TALi as a Board member and new Chair is Mark Simari. Mark served as a TALi Board member from 2016 through 2020. TALi are excited to welcome him back to the Board as Chair and look forward to leveraging his experience from the financial and investment markets.

"I would like to thank the Directors for welcoming me back to the company and I look forward to working with the team to support the TALi strategy and vision whilst representing the best interest of shareholders. I would also like to thank Sue & Jefferson on their commitment to the TALi journey during their tenure and wish them well with their future endeavours"

The Board, under the leadership of Mark Simari, will look to fill the vacant position as soon as possible.

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Dr Mary Beth Brinson
Chief Executive Officer
TALi Digital
1300 082 013
investors@talidigital.com

Investors

Betsy Syme
Investor Relations
TALi Digital
1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.